- 面议
起订量：
79854 Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transm...
- 型号
- 79854
该企业相似产品
BPS Bioscience专注于开发高质量的产品，提供优质的客户服务，并维护稳健的质量管理体系。BPS Bioscience现已通过ISO 9001:2015认证，确保质量的持续监控和持续改进，从而满足客户需求。
BPS Bioscience产品涉及临床前药物开发过程的每个阶段。其中部分产品可以用于许多研究阶段。BPS Bioscience将继续丰富我们的产品线，希望以此推动了整个早期药物研发过程。
详细信息
Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transmembrane Motif) is a stable cell line expressing an anti-CD19 CAR negative control and an NFAT-dependent luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without the intracellular signaling domains. The reporter cell line has been validated for anti-CD19 expression by flow cytometry, and in co-culture with target cells, such as CD19/CHO recombinant cell line the luciferase reporter gene was not activated. Anti-CD19 CAR Negative Control Jurkat/NFAT (Luciferase) Reporter Cell Line was generated by the transduction of NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) with anti-CD19 CAR negative control lentivirus.
The cell line can be used as negative control for the Anti-CD19 CAR/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1-BB-CD3ζ) (BPS Bioscience #79853).
Figure 1: Lenti-vector used to generate anti-CD19 CAR negative control lentivirus.
Figure 2. Schematic of anti-CD19 CAR negative control.
The anti-CD19 (scFv) is linked to the CD28 transmembrane motif.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
